Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients

被引:17
|
作者
O'Brien, Daniel P. [1 ,2 ,3 ]
Friedman, Deborah [1 ]
Hughes, Andrew [1 ]
Walton, Aaron [1 ]
Athan, Eugene [1 ]
机构
[1] Barwon Hlth, Dept Infect Dis, Geelong, Vic, Australia
[2] Univ Melbourne, Royal Melbourne Hosp, Dept Med & Infect Dis, Melbourne, Vic, Australia
[3] Med Sans Frontieres, Manson Unit, London, England
关键词
Mycobacterium ulcerans; antibiotic treatment; complication; adverse effect; Australia; ORAL MEDICAL THERAPY; BURULI ULCER; CLINICAL-FEATURES; DRUG-INTERACTIONS; INFECTION; COHORT; PHARMACOKINETICS; FLUOROQUINOLONES; CLARITHROMYCIN; EPIDEMIOLOGY;
D O I
10.1111/imj.13511
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Antibiotics are the recommended first-line treatment for Mycobacterium ulcerans disease. Antibiotic toxicity is common in Australian patients, yet antibiotic complication rates and their risk factors have not been determined. Aim: To determine the incidence rate and risk factors for antibiotic toxicity in Australian patients treated for M. ulcerans disease. Methods: An analysis of severe antibiotic complications was performed using data from a prospective cohort of M. ulcerans cases managed at Barwon Health from 1 January 1998 to 30 June 2016. A severe antibiotic complication was defined as an antibiotic adverse event that required its cessation. Antibiotic complication rates and their associations were assessed using a Poisson regression model. Results: A total of 337 patients was included; 184 (54.6%) males and median age 57 years (interquartile range (IQR) 36-73 years). Median antibiotic treatment duration was 56 days (IQR 49-76 days). Seventy-five (22.2%) patients experienced severe antibiotic complications after a median 28 days (IQR 17-45 days) at a rate of 141.53 per 100 person- years (95% confidence interval (CI) 112.86-177.47). Eleven (14.7%) patients required hospitalisation. Compared with rifampicin/clarithromycin combinations, severe complication rates were not increased for rifampicin/ciprofloxacin (rate ratio (RR) 1.49, 95% CI 0.89-2.50, P = 0.13) or rifampicin/moxifloxacin (RR 2.54, 95% CI 0.76-8.50, P = 0.13) combinations, but were significantly increased for 'other' combinations (RR 2.53, 95% CI 1.13-5.68, P = 0.03). In a multivariable analysis, severe complication rates were significantly increased with reduced estimated glomerular filtration rates (EGFR) (adjusted rate ratio (aRR) 2.65, 95% CI 1.24-5.65 for EGFR 60-89 mL/min and aRR 1.31, 95% CI 0.49-3.53 for EGFR 0-59 mL/min compared with EGFR = 90 mL/min, P <0.01) and female gender (aRR 2.15, 95% CI 1.38-3.30, P <0.01). Conclusions: Severe antibiotic complications during M. ulcerans treatment are high with increased rates independently associated with reduced renal function and female gender.
引用
收藏
页码:1011 / 1019
页数:10
相关论文
共 50 条
  • [1] Spontaneous healing of Mycobacterium ulcerans disease in Australian patients
    O'Brien, Daniel P.
    Murrie, Adrian
    Meggyesy, Peter
    Priestley, Jonathan
    Rajcoomar, Avinash
    Athan, Eugene
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (02):
  • [2] Dynamics of the Cytokine Response to Mycobacterium ulcerans during Antibiotic Treatment for M-ulcerans Disease (Buruli Ulcer) in Humans
    Sarfo, F. S.
    Phillips, R. O.
    Ampadu, E.
    Sarpong, F.
    Adentwe, E.
    Wansbrough-Jones, M.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (01) : 61 - 65
  • [3] Corticosteroid Use for Paradoxical Reactions during Antibiotic Treatment for Mycobacterium ulcerans
    Friedman, N. Deborah
    McDonald, Anthony H.
    Robson, Michael E.
    O'Brien, Daniel P.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (09):
  • [4] Treatment costs of Mycobacterium ulcerans in the antibiotic era
    Pak, Jason
    O'Brien, Daniel P.
    Quek, Tricia
    Athan, Eugene
    [J]. INTERNATIONAL HEALTH, 2012, 4 (02): : 123 - 127
  • [5] Mycobacterium Ulcerans Treatment - Can Antibiotic Duration Be Reduced in Selected Patients?
    Cowan, Raquel
    Athan, Eugene
    Friedman, N. Deborah
    Hughes, Andrew J.
    McDonald, Anthony
    Callan, Peter
    Fyfe, Janet
    O'Brien, Daniel P.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (02):
  • [6] Mycobacterium ulcerans disease management in Australian patients: the re-emergence of surgery as an important treatment modality
    O'Brien, Daniel P.
    Callan, Peter
    Friedman, N. Deborah
    Athan, Eugene
    Hughes, Andrew
    McDonald, Anthony
    [J]. ANZ JOURNAL OF SURGERY, 2019, 89 (06) : 653 - 658
  • [7] Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease
    Fred S Sarfo
    Richard O Phillips
    Jihui Zhang
    Mohammed K Abass
    Justice Abotsi
    Yaw A Amoako
    Yaw Adu-Sarkodie
    Clive Robinson
    Mark H Wansbrough-Jones
    [J]. BMC Infectious Diseases, 14
  • [8] Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease
    Sarfo, Fred S.
    Phillips, Richard O.
    Zhang, Jihui
    Abass, Mohammed K.
    Abotsi, Justice
    Amoako, Yaw A.
    Adu-Sarkodie, Yaw
    Robinson, Clive
    Wansbrough-Jones, Mark H.
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [9] Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease
    Converse, Paul J.
    Xing, Yalan
    Kim, Ki Hyun
    Tyagi, Sandeep
    Li, Si-Yang
    Almeida, Deepak V.
    Nuermberger, Eric L.
    Grosset, Jacques H.
    Kishi, Yoshito
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (01): : 52
  • [10] Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease
    Sarfo, Fred Stephen
    Converse, Paul J.
    Almeida, Deepak V.
    Zhang, Jihui
    Robinson, Clive
    Wansbrough-Jones, Mark
    Grosset, Jacques H.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2013, 7 (03):